Neurocrine Biosciences Inc at Canaccord Genuity Growth Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : Sure, thanks. So you touched upon this a little bit. It's really nice to see the bench strength that Neurocrine had. So you're now in the CEO elect position. So what are kind of goals you've set yourself over the next few quarters as you take over the role.

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : So that's a great overview, and you have a large pipeline, right? And you kind of grew up on the business development side of things. So how do you expect that business development philosophy to change when you are CEO, especially with respect to the stage of product that you might want to get in? Or are you going to be internally focused for some time now, given all the stuff that's going on? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 14, 2024 / 7:30PM, NBIX.OQ - Neurocrine Biosciences Inc at Canaccord Genuity Growth Conference

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : So you mentioned clearly, that product has done really well. You were one of the few biotech stocks that could buck their [lets chart] the launch trend, and you did that really successfully. So it's been out in the market for a few years. What do you think the most important source of growth can be from here? Is it new patient starts? Is it something else?

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : And then we know the product is some promotional sensitive, right? So what's the type of promotion that gets you the best bang for the buck? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 14, 2024 / 7:30PM, NBIX.OQ - Neurocrine Biosciences Inc at Canaccord Genuity Growth Conference

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : So you brought up a good point, which is 14 more years of product exclusivity for patent protection, like not exclusively but patent protection -- so at what point would you consider a step change in investment on the sales force side might be needed? Because you've had it.

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : But what's the next --?

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : Got it. And let me --

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : Got it. So let's move on to the pipeline now. You have you have a [muscular index] portfolio, that's probably an understatement. It's a hot area of neuropsychiatry, probably also an understatement. So with 568 with the Phase II data that's coming -- you've mentioned in the past that an 8-point delta on the scale might be something to keep in mind on this product. What gives you confidence that this bar might be able to be achieved? And what might be something that might make it not able to be achieved?

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : So you alluded to this a little bit, but what do you think the highest value indication might be for muscular agonists as things stand?

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : Yes. So let's pass forward to a time when maybe there are several muscular agonistics approved for schizophrenia. It's already a fairly well-penetrated market in terms of medications available those clearly have downsides in terms of side effects as well. So how do you see the second, third core product playing out you're on the market for schizophrenia with a muscular antagonist?

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : Let's move on to luvadaxistat now for cognitive impairment associated with schizophrenia, or CIAS, that is a really challenging indication. It's several new psychiatric indications are challenging, but that one kind of almost takes the cake. So what gives you confidence that luvadaxistat might work in CIAS.

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : So you are Neurocrine focus on the neuro part, let's go to the crine part. So crinecerfont, we have pending approvals in pediatric and rare patients later this year. Do you expect the product uptake to be different in those two types of markets? And why do you have any preliminary thoughts on pricing that you can share? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 14, 2024 / 7:30PM, NBIX.OQ - Neurocrine Biosciences Inc at Canaccord Genuity Growth Conference

Question: Sumant Kulkarni Kulkarni - Canaccord Genuity - Analyst : We'll switch back to 845 in the last few seconds we have here for inadequate response to treatment in major depressive disorder, MDD. What do you think the key discussion points there might be as you meet with the FDA on a Phase II program.